• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    An inhalable cyclodextrin for use in the treatment and prevention of late phase bronchoconstriction in allergen-induced asthma is disclosed. The use of a cyclodextrin in the treatment and prevention by inhalation of late bronchoconstriction in allergic asthma is also disclosed.
    公开号:BE1028268B1
    申请号:E20215463
    申请日:2021-06-13
    公开日:2021-12-02
    发明作者:Didier Cataldo；Brigitte Evrard
    申请人:Univ Liege；
    IPC主号:
    专利说明:

    Cyciodextrin used in the treatment and prevention of late stage bronchoconstriction in asthma caused by allergens
    TECHNICAL FIELD Lashma is a complex and multifactorial disease characterized by chronic inflammation of the respiratory tract which affects more than 300 million people worldwide. Lashma causes constriction of the airways, called bronchoconstriction, There are two forms of asthma, asthma not caused by allergens and asthma caused by allergens, HISTORY OF THE INVENTION Asthma In asthma induced by allergens, an inflammatory response is generated by the antigens, This response involves different types of cells of the internal and adaptive immune system, These cells recruit and activate inflammatory cells, resulting in bronchial hyperreactivity, overproduction of mucus and remodeling of airway wall. Membrane lipid microdomains regulate cell signaling cascades. These include complex hipid-protein interactions and the clustering of specific receptors. Cholesterol is a key part of the fluid-ordered domains on the cell membrane, called lipid rafts. Linicia rafts are also involved in allergen presentation and subsequent activation of T cells by localized enrichment of MHC class II months on the surface of antigen presenting cells. Early phase reaction in allergen-induced asthma Early phase bronchoconstriction usually occurs immediately after exposure to ailergen. Mast cells produce mediators that cause changes in the airways. Some mediators immediately cause inflammation in the early phase.
    Late phase reaction in allergen-induced asthma The late phase reaction occurs approximately two to four hours after initial exposure to an antigen, Mediators induce chiriotactic recruitment and activation of ecsinophils and neutrophils during ta late phase reaction.
    Reinforcements cause persistent inflammation of the airways. This makes the airways increasingly hypersensitive to triggers (asthma increases the risk of future asthma attacks. The late phase can last from 12 to 24 hours. Cyclodextrin for the treatment of puimonial disorders Cyclodextrins have been proposed for the treatment of puimonial disorders, including asthma: EP1799231 at the University of Liège discloses the use of a cyclodextrin compound for the manufacture of a medicament for the treatment and prevention of inflammatory diseases of the bronchi, in particular asthma.
    EP290C246AT to SolAeromed discloses the use of methyl-beta-cydlodextrin for the treatment of puimonial aurfactant dysfunction. This publication claims that the oxidative damage of pulmonary surfactant is due to the interaction between reactive species of eugene and cholesterol, It further claims that methyl-beta-cvelodextrin can restore normal functioning of a withdrawn dysfunctional surfactant. lungs of children with cystic fibrosis and non-cystic fibrosis bronchiotitis.
    US2010173869A1 to Solieromed discloses a method of treating a surfactant, in particular a pulmonary surfactant. The surfactant is treated with a lipid or cholesterol sequestering surfactant treatment agent, in which neutral lipids or cholesterol, in particular, are selectively segested by means of the surfactant treatment agent, so that the surfactant effect of lipids and / or the effect of cholesterol on the surfactant is reduced or reversed. US2013029937A1 to SolAeromed discloses a method for improving a cyclodestrins surfactant. The document deals with a method of alleviating oxvdative damage to lung surfactants by adding eycladextrin as a cholesterol sequestering agent. This publication also presents a method of treating a patient with surfactant dysfunction due to an oxidative damage of the pulmonary surfactant by the administration of a protective amount of a cyclodextrin surfactant as a cholesterol sequestering agent to protect the surfactant from the negative effects of oxidative degradation, Finally, EPSISISISAT at [University of Liège and Paul Maes discloses pharmaceutical compositions formulated with an oyclodestrine compound, in particular HPRCD and a budesonide derivative for the treatment and / or prevention of puimonial inflammatory diseases, However, none of the above publications reveal the crucial difference between the treatment of the phase early stage and that of the late phase of asthma induced by pa r allergens.
    Thus, there is still an urgent need to improve the efficacy of cyclodextrins in the treatment and prevention of asthma caused by allergens. The current inventors have now surprisingly discovered that cyclodextrin can be used in the treatment of phased branchoconstriction. late in mild to moderate asthmatics.
    Applicants suggest that cyclodextrins cause a disruption in the organization of T cell membranes of the lungs which hinders their activation after recognition of allergens. BRIEF DESCRIPTION OF THE INVENTION A first aspect of the invention is an inhalable cyclodextrin or derivative. pharmaceutically acceptable solution thereof, for use in the treatment or prevention of late phase bronchoconstriction in asthma induced by altergens.
    In another aspect, the cyclodextrin is Hydroxypronyl-beta-cyclodextrin.
    In another embodiment, the oyclode = trine is an inhalable aqueous solution,
    In another embodiment, the concentration of cyvclodextrin is 5 millimoles to SC millimoies. In another embodiment, the concentration of cyclodextrin is 7 millimoles to 40 millimoles.
    In another embodiment, the concentration of cyclodedrine is 10 to 30 mittimotes. In another aspect, the cyclodextrin is a spray dried powder. In another embodiment, the cyvclodextrin is administered in an amount effective to reduce the order of membranes in the cells. In another embodiment, the cyclodextrin is administered by inhalation at a rate of 0.1 to 30 me per day.
    In another embodiment, the cyclodextrin is administered by inhalation at a rate of 0.5 mg to 20 ml per day. In another embodiment, the cyclodextrin is administered by inhalation at a rate of 1 minute per day.
    In another embodiment, cyclodextrin is administered to children up to two years of age by inhalation at 0.1 mg to 0.5 mg per day.
    In another embodiment, cyclodextrin is administered to children aged two to six years by inhalation at a rate of 0.5 mg to 1 mg per day.
    In another embodiment, cyclodextrin is administered to children aged 6 to 14 years by inhalation at a rate of 1 to 2 mg per day.
    In another embodiment, cyclodextrin is administered at a rate of 0.1 m to 15 mg per day in mild to moderate allergen-induced asthma and 1 mg to 30 m in severe allergen-induced asthma, Another aspect of the invention is a method of treating T cell dysfunction in puimonial tissue, wherein cyclodextrin is administered by inhalation in an amount effective to reduce the cell membrane order in sulets exhibiting the dysfunction. T cells in their puimonaire tissue, preferably without causing side effects limiting the treatment,
    such as those selected from the group consisting of renal clarity, hepatic insufficiency expressed by high levels of tramaminase, and wheezing after administration, compared to subjects not treated with cyclodestrine, In another aspect of the treatment. A method of treating 3 T cell dysfunction, acyclodextrin is administered by inhalation as 15 mM isotonic saline HPBCD solution.
    In another aspect of the method of treating T cell dysfunction, cyclodextrin is administered by inhalation as a solution based on HPBCD PBS, ph7.4, 15 mMoL 19 In another aspect of the method of treatment For T cell dysfunction, cyclodextrin is administered by inhalation as Kotoric Saline HPSCD, 5 mMol.
    In another aspect of the method of treating T cell dysfunction, cyclodextrin is administered by inhalation as a solution based on HPECD PES, pn7.4, 25 mMol. In another aspect of the method of treating T cell dysfunction. T cell dysfunction Cyclodextrin is administered by inhalation as 40mMol HPSCD satine iotonic solution. In another aspect of the method of treating T cell dysfunction, eycladextrin is administered by inhalation as 25 mol HPBCD satine sodium hydroxide solution. In another aspect of the method of treating T cell dysfunction, cyclodextrin is administered by inhalation as a 10 ml HPBCD citrate pH 45 In another aspect of the method of treating T cell dysfunction. Treatment of T cell dysfunction, cyclodextrin is administered by inhalation as HPBCD citrate of AQ mMol DH 4.5, In another aspect of the method of tr In response to T cell dysfunction, cyclodextrin is administered by inhalation as a 50 mMot HPRCD iotonic saline solution,
    $ BE2021 / 5463 Cyclodextrins can be administered in bolonkus solution WHERE A hypertonic solution, A solution is sotonic when its effective osmole concentration is the same as that of the cytosol inside the cell and in particular respiratory cells, preferably cells of the puimonary mucosa. A hypertonic solution is said to be hypertonic if it has a greater concentration of solutes than the cytosol inside the cell and in particular respiratory cells, preferably cells of the pulmonary mucosa. furthermore, it is preferable that the pH of the composition is adjusted to 3.5-7.5, preferably d5a7. In order to adjust the pH, surface tension, viscosity, osmolativity, stability, taste and other properties of the composition, one or more other excipients can be used.
    For example, the composition may comprise one or more excipients chosen from pharmaceutically acceptable organic acids, salts of organic acids, inorganic acids, inorganic salts, bases, sugars, sugar alcohols, stabilizers, antioxidants, surfactants, preservatives and flavor masking agents.
    DETAILED DESCRIPTION OF THE INVENTION The current inventors have surprisingly discovered that cyclodextrin can be used to extract lipids or reduce the order of the membrane of epithelia cells and in particular of the membrane of T cells of the lung parenchyma.
    Reduction of membrane order per cyclodestrine inhalation results in decreased activation and proliferation of T cells, Activation and profiferation of T cells impact late phase bronchoconstriction in allergen-induced asthma Thus, a first aspect of the invention is an inhalable cyclodextrin or a pharmaceutically acceptable cyclic derivative thereof for use in the treatment of late phase bronchoconstriction of allergen-induced asthma,
    Definitions The term “asthma” describes a disease causing chronic inflammation and constriction of the airways. The term “bronchoconstriction” refers to the constriction of the airways in the lungs due to tightening of the surrounding smooth muscles, resulting in coughing, breathing. wheezing and shortness of breath due to an immunologic reaction involving the hiberation of inflammatory mediators.
    In one case, bronchoconstriction is measured by a decrease in FEV1.
    The term FEVT "describes the forced expiratory volume in 1 second.
    FEV1 is the volume of air that can be forcibly exhaled in one second after a full inspiration. up to 60 minutes after exposure to the ailergen.
    The term “late phase” bronchocanstriction describes bronchoconstriction from 180 minutes to 360 minutes after exposure to allergen.
    An example of late phase bronchoconstriction is a 15% decrease in FEV1 from 180 minutes to 360 minutes after exposure to allergens.In some cases, late phase bronchoconstriction lasts for several hours, for example from 180 minutes to five, six , smells, eight, nine or ten hours after exposure to allergens.
    In some cases, the late phase can last up to 24 hours after exposure to the allergens. The expression "membrane disorder" or "reduction in membrane order" means a reduction in the organization and stiffness of the membranes. cells, in particular membranes of cells 7 of the lung parenchyma.
    In one case, the membrane order disorder means an increase in the mobility and polarity of phosphotipids in T cell membranes.
    In a life form, the mobility and polarity of phospholipids are measured by labeling with fluorescers such as Laurdan or by staining sections of lungs blue.
    The dynamics and fluidity of lipids at the acyl chain after incubation of cyclodestrin can be measured at 37 degrees Celsius, Anisotropy at 37 degrees Celsius can be used to measure membrane rieldity.
    An example of one way to measure membrane disorder or reduction in membrane order is given in Example 1 below.
    The term "protiferation of T ° cells means an increase in T cells over a period of time. In another embodiment, the proliferation of Test lymphocytes measured by flow cytomeetry analysis of TH2 cells of the lung and by counting total leukocytes. example of a method for measuring the proliferation of T tyrnphocytes is given in [Example 1 below.
    In one application, naive CD4 + T cells are exposed to a concentration of 5 mM HPECD and anti-CD3 {3 meg / mt) for 24 hours or 48 hours with HPBCD {5 mA} or with a 19 culture medium alone at 37 ° C. 5% COZ. During the last 2 hours of the profiferation test, bromodeoxyuridine is added to the medium and the incorporation is quantified by ELISA.
    The secretion of iL-2 is measured in the medium after 24 hours and 48 hours of anti-CD3 stimulation by ELISA.
    The term “treatment” or cure ”describes inhalation of a cyclodextrin to reduce late stage bronchoconstriction in asthma.
    In particular, the term “treatment describes inhalation of a cyclodextrin to reduce the order of the membrane of F cells. The term“ prevention ”describes any reduction in the risk of late-phase bronchoconstriction of asthma by (inhalation of a coyclodextrin.
    In particular, the term "prevention" describes the inhalation of a cyclodextrin to reduce the order of the T cell membrane.
    The terms "effective amount" or "therapeutically effective amount" as used herein refer to an amount of an active agent as described herein which is sufficient to achieve, or help achieve , one or more desirable clinical results, such as those described in the description of "treatment" above. An appropriate "effective" amount in each individual case can be determined using standard techniques known in the art, such as a dose escalation study.
    In some instances, as used herein, the term "therapeutically effective amount" means an amount of an active agent or combination of agents effective to ameliorate, delay or prevent symptoms,
    The term "oyclodextrin" describes oligosaccherides composed of glucopyranose units. The main unsubstituted cyclodextrins are generally prepared by the erzymatic degradation of starch. 3 tyclodextrins, respectively comprising 6, 7 and 8 glucopyranose units.
    In another variant of the invention, oyclodextrin derivatives are used, for example chemically modified cyclodextrins, which may have a greater solubility in water than unmodified cyclodextrins.
    Among the examples of such derivatives, mention may in particular be made of Z-hudroxvoropyl-beta-cyclodextrin (HPBCD}, 152 2-hydrocypropyl-gammaæ-cyclodextrin (HPGCD}, sulffobutyiether-beta-cyclodextrin {SBEBCD} and methyl- beta-cyclodextrin (MBD). The term "pharmaceutically acceptable derivative" of a cyclodextrin describes cyclic organic compounds derived from cyclodextrins which are capable of creating disorder of the epithetial membrane in the lung parenchyma to an extent comparable to cyclodextrins. aqueous ”as used herein refers to a composition comprising at least one cyclodextrin, water and optionally one or more other components suitable for use in pharmaceutical administration such as carriers, stabilizers, diluents , dispersing agents, suspending agents, spelling agents, excipients and the like.
    In some cases, the pharmaceutical composition is free from aipha or gamma-cyclodextrin.
    The term 'active pharmaceutical ingredient' denotes any substance or combination of substances used in a finished pharmaceutical product, intended to exert pharmacological activity or to have a direct effect on the diagnosis, cure, alleviation, treatment or prevention of a disease. disease, or to have a direct effect on the restoration, correction or modification of physiological functions in humans.
    Preferably, the term "active pharmaceutical ingredient" denotes a molecule intended to be bicologically active, for example to treat an inflammatory, autoimmune or puimonial disease, disorder or condition, 38
    Reduction of the order of T cell membranes The current inventors have surprisingly discovered that cyclodextrin can be used to extract Hpids or reduce the order of the membrane of epithelial cells and in particular of the membrane of T cells of the parenchyma. puimonaire. Reduction of membrane order by inhalation of cyclodestrine leads to decreased activation and protiferation of T cells, Activation and protiferation of T cells impact late stage bronchoconstriction in asthma induced by allergens. Thus, a first aspect of the invention is an inhalable cyclodextrin or a pharmaceutically acceptable cyclic derivative thereof for use in the treatment of late phase bronchoconstriction in allergen-induced asthma. The inventors also show that the cyclodextrins administered by inhalation reduce the inflammation induced by the allergens and the associated hyperreactivity in the bronchoconstriction induced by the allergens.
    In another embodiment, the cyclodextrin of the invention is used to reduce T cell proliferation or T cell activation. In addition, the current inventors have found that cyclodextrins may have no impact on T cell. early stage asthma.
    The cyclodextrin of the invention is Hydroxypropyl-beta-cyclodextrin. In another aspect, asthma is mild to moderate asthma induced by allergens. Another aspect of the invention is a composition comprising a cvclodectrin or a pharmaceutically acceptable cyclic derivative thereof for use in the treatment of late phase bronchoconstriction of allergen-induced asthma. Amount, concentration and dosage The cyclodextrin of the present invention is used to treat or prevent late-phase bronchoconstriction of the esthma caused by allergens. It is
    | ; BE2021 / 5463 given as a single dose to patients with late bronchoconstriction in (allergic asthma. H is given in an amount sufficient to reduce bronchoconstriction in late phase asthma compared to patients on placebo.
    In one form of administration, the cyclodextrin is administered in a daily dose of 0.1 to 30 mg, preferably 0.5 to 20 me, about 1 to 10 me, and even more preferably about 5 to 10 me. In another variant, cyclodextrin is administered to children aged two years or less by inhalation at a rate of 0.1 to 0.5 ma per day. 19 Cyclodextrin is administered by inhalation to children aged two to six years at doses of 0.5 mg to 1 mg per day. Cyclodextrin is given to children aged 6 to 14 years by inhalation, at a dosage of 1 to 2 mg per day, Cyclodextrin is given at a dosage of 0.1 mg to 15 me by oven in mild to moderate allergic asthma and from 1 mg to 30 me in severe allergic asthma. Cyclodextrin is administered once a day by inhalation. In another variation, the cyclodextrin is administered twice daily by inhalation, preferably once in the morning and once in the evening. In another variation, the cyclodextrin is administered three times per day by inhalation, preferably once in the morning, once at noon and once in the evening. However, a greater number of inhalations per day can be expected, for example four, five, six or seven times per day. Cyclodextrin is a liquid composition comprising cyclodextrin in the range of 1 mg / ml to 100 ml / ml, preferably from 5 mg / ml to about 50 mg / ml, and more preferably from 10 mg / ml to about 30 mg / ml, Other preferred concentrations are from 15 mg / ml to 25 mg / ml, In another alternatively, the concentration of cyclodextrin in the composition of the liquid is between 1 and 100 millimoles, preferably between 3 and 80 millimoles, more preferably still between 5 and 50 millimoles, more preferably still between ie BE2021 / 5463 7 and 40 millimoles, nis more preferably between 10 and 30 millimoles, and more preferably still between 12.5 and 17.5 millimoles. Other Ingredients In one of its forms, cyclodextrin is combined with another active pharmaceutical ingredient. In another version, no other active pharmaceutical ingredient is associated with the tyclodextrin of the present invention. In another embodiment, the inhelable composition further comprises a component selected from the group consisting of carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, excipients and antimicrobial preservatives, In AQueLses Solutions these components are present in small amounts, generally in the range of 0.1 mg / ml to 5 me / ml 13 Another aspect of the invention is the use of a coyclodextrin or a composition of the invention in the treatment and prevention by inhalation of late phase bronchoconstriction in allergen-induced asthma. Another aspect of the invention is an aerosol generator device or a dry powder inbalator comprising cycladestrine or the composition of the invention.
    BRIEF DESCRIPTION OF THE DRAWINGS Fig, 1 Fig 1 shows how HPBLD protects against infammation | induced by aliergens and assisted reproduction in mice | Fig, 1a Protocol for inflammation induced by HDM and [9 airway hyperreactivity, intranasal 100mes / 50mct | Fig. 18 Respiratory function tests after exposure to increasing doses of methachoiine from 3 to 12 mg / ml and pulmonary resistance of bass sans | methachoiine. |
    , BE2021 / 5463
    Fig, 10 BALF cells count ecsinophites, lymphocytes, neutrophites | Fig, 1D Lung sections stained with thematoxylin and [eosin and scores | of inflammation 8 Akcan blue stain of lung sections | Fig, 1F Flow cytometric analysis of TH2 lung cells and 8 total leukocyte count | Fig. in Figure 2 shows how the HPECD targets the reactivity and inflammation of the airways induced by Vovalbumin, | Fig, 2A Protocol for OVA-induced inflammation and AHR inhalation, | Fig. 28 “Resistance measurement of the respiratory tract Gite am challenges of methachoiin with |
    Increase the doses (3-24 mg / ml and basic pulman resistance | without methacholine.
    Rn, Newiornian Resistance. 8
    Fig, 20 Cell contents in BALF, Eosino, ecsinophils; Lympho, | mphocytes, Neutral, | neutropivites, 8
    Fig, 20 Congo red spots representative of lung sections and | ve number of deosinophils / mm of basement membrane. | Fig.
    ZE Percentage of eosinophies {%} in BALF in animals treated with 8 HPBCD, linear dextrins and glucose. | Peribronchial inflammation scores. 8 Fig. 2E-F | n-7-Bmice / uroupe, Average + / 3.e, m, one-way dANOVA test, * | P <0.05, PeQ, 01t, ** P <Q, 001, Data are representative of two | a independent experiences. 8 Fig, 3 Figure 3 shows how the HPECD reduces the proffferation of | T cells in the heath-draining lymphatic ganghions (LDLN}. | Total number of cells in LDEN 8 Fig, 3B Flow cytometric analysis of DC-OVA + {F4 / 80- CD1T1c + MHCH-) in | your LDLN | in 8
    LDLN. |
    Fig. 3A-B N = 7 mice / group, means +/- wk, two-tailed Mann-Whitney test, | * P <G, 05, The data are representative of at least two independent experiments 8, | Fig. + Figure 4 shows how the extraction of fipids by FRS hinders the activation and proffferation of glues T, 8 Fig, dA Phase separation study (liquid-ardered {lo} - liguid-disordered | {di} in the GUYs (TR-DPPE (red, ld}; NBD-PE (green, lo) following the incubation of HPBCD (5 mM). | Fig. 45 GPex (n = 6} and antsotropy {n = 23} on cells of jurkat (HPBCD (5 me | 3 h incubation, | Fig, 4C Study of protiferation (incorporation of Brol + n =) and secretion 8 of iL-2 in the culture medium (ELISA - n = 6} on new CDd + T cells | a {Balb / c} stinulated by anti-CD3 fixed on plate (3 ja / mih, | Fig, 4D Ex-vivo restimulation study of LDLN cells, ELISA measurement of IL, 8 rem Bet - 13 secreted, | Two-tailed paired t-test. 8 Fig, dE DC lung flow cytometry (F4 / 80- CD11c + MHC) for | OVA-FITT expression and MHCH {MFI} n = 6 mice / group, means + / -z, e, m, | two-tailed Mann Whitney test, Data are representative of 8 two experiments ind dependent. | Fig, 5 Fig. 5 shows how the bronchoconstriction induced by inhaled HPBCD allergens in a proof-of-concept clinical trial 8 Clinical trials profile. | Fig. 58 Change in FEV1 (%} from the reference value following the 8 provocation by Allergens (HDM), | Fes EVA of a decrease in the percentage of FEV1 adjusted to the terms at baseline) during the early {0-60 min) and late {180-360 min} {BE} phases. | Fig.
    SE Mean percent decrease in FEV1 during the early (0-60 8 min} and late (180-360 min) phases. | Fig. 5842 | Ne15 mild to moderate asthma patients, means "/ - ser, a test | Le de Wilcoxon tail in paired pairs. 8
    EXAMPLES The following examples illustrate the present invention without limiting its scope.
    Figures 1 to 5 illustrate the examples in more detail.
    Abbreviations APCs ARR antigen presenting cells.
    Airway hyperresponsiveness AUC FEVT curve as a function of time BALF Bronchoaiveolar lavage fluid Bra Sromocessoxyuridine ELISA Immunosorbent test [ie to an FEV enzyme Forced expiratory volume after a second CPE Good clinical practices GUVS Giant unilamellar blisters HDM Dust mites Homemade HPBCD Hydroxypropyl-beta-cyclodestrine in, intranal instillations Liguid-disordered LLN Yymphalic gangtions that drain the lungs Houide order meg microgramimecrotitre PBS Phosphate buffered saline solution PD20 Provocative dose that causes a 20% drop in FEV1 POPL t-palmitoy-2-0leovsnghréro-3-phosphocholine Rn Newionian resistances SEM Standard error of the mean TRM T cells of long-term memory residents
    Example Ÿ: 15 mol HPESCD healthy isotonic solution Dissolve 21.73 grams of Meptose® HPSCD (HP-Betadex, available from Roquette Frères, France) and 8.54 grams of NaCl in 1 tre of water for injection, where steritize at water vapor, Example 2: solution based on 15 mMol of HPBCD PBS 957.4 Dissolve 21.73 grams of Kleptose® HPBCD (HP-Betadex): 7th from Natl; 0.29 KUL: 1 Ada Na2HPO4; D, 24g of KHZPO4 in 800 ml of sterile water. Adjust the pH to 7.4 with HOLD, IN, Adjust the volume to 1L with additional distilled H2O. Sterilize by autociave or dispense into sterile vials using 19 micron and 0.22 micron double filtration. Example 3: Healthy Sotonic HPRCD Solution of 5 mMol Dissolve 8.75 grams of Kleptose® HPRCD® (HP-Betadex) and 8.74 grams of NaCl in 1 liter of water for injection, or steam steritize. Example €: solution based on HPBCD PBS of 25 mMol, ph7.4 Dissolve 36.22 grams of Kleptoss® HPBCD (HP-Betadex}; 6.479 of NaCl; 0.48 of KC: 1.449 of NaZHPO4; 0.249 of KH2PO4 in 800 ml of sterile water Adjust the pH to 7.4 with HOLD, IN, Adjust the volume to 1L with additional distilled H2O, Autociave or dispense into sterile vials using 5 double filtration microns and 0.22 microns.
    Example 5: 40 mol HPECD sotonic saline solution Dissolve 57.91 grams of Kleptose® HPBCD (HP-Betadex) and 7.94 grams of NaCl in 1 liter of water for injection, or steam steritize. Example &: 25 mMol HFECD healthy Kotonic solution Dissolve 36.22 grams of Klentose® HPECD (HP-Betadex and 8.74 grams of NaCl in 1 liter of water for injection, or steam sterilize. Example 7: solution 10 mol of HPBCD citrate pH4.5 Dissolve 17.45 grams of Kleptose® HFECD (HF-Betadext; 8.272 of NaCl: 0.3068 of citric acid monchydrate, 0.5008 of sodium citrate dihydrate in 800 ml of sterile water. {Adjust the pH to 4.5 with MCLO, IN or 0.1N NaOH if necessary), Adjust the volume to 1L with additional distilled H2O.
    Autociave or dispense into sterile vials using 5 micron and 0.22 micron dual filtration.
    Example $: 40 mMoi solution of HPBCD citrate, pH4.5 Dissolve 57.91 grams of Keptose® HPBCD (HP-Betadex}; 7.97g of NaCl; 0.3060 citric acid monohydrate, 0.5009 of sodium citrate dihydrate in 800 ml of sterilized water. {Ahster the pH to 4.5 with MULO, IN or NaQH 0, IN if necessary), Adjust the volume to 1L with (additional distilled H20, Sterilize in autociave or distribute in sterile vials using 5 micron and 0.22 micron double filtration 128 Example $: 50 metol HFBCD hotonic saline solution Dissolve 72.38 grams of Kleptosed HPECD {HP-Hetadex} and 7.77 grams of Naf! in 1 liter of water for injection, {or steam sterilize with hot water) Example 10: Inhalation of HPRCD reduces allergen-induced inflammation and airway hyporeactivity Impact of MPSCD on bronchial inflammation and hyperreactivity associated with asthma has been studied in a raurine model of inflammation and hyperresponsiveness of the airways. ires.
    Six to seven mice per group were tested. A two-tailed Mann-Whitney test was performed with p-values of P <0.05, ŸP <0.01 in two independent experiments.
    Two intranasal instilations of mites were performed on days D and 7 to induce migration of CD4 + specific memory T cells in the lung parenchyma, followed by a challenge instillation on day 14. lungs are associated with a low level of proliferation but are very effective against known allergens.
    The last instilation of mites was preceded by two days of HPECD or PES inhalations and followed by three inhatations until sacrifice (Figure 14). Airway hyperresponsiveness is a hallmark of laste and is primarily induced by structural changes and inflammation of the airways.
    Airway responsiveness was assessed by exposing animals to increasing doses of inhaled msthacholine and by measuring Newtonian resistances representing resistance of the central or conductive airways.
    The inventors observed that the disruption of HPBCD significantly decreased the reactivity of the airways to methachoine, while the baseline reactivity was similar between the groups (FIG.
    18), Bronchoalveolar lavage fluid (BALF) was then collected and analyzed for cell content.
    The eosinophilic inflammation associated with exposure to allergens was significantly reduced in animals exposed to HPBCD compared to placebo (Figure 10), The extent of inflammation around the bronchi {Figure
    1D; and the number of positive Alcian blue mucus-producing epithelial cells (Figure 1E) were also reduced when mice were treated with HPBCD compared to placebo. The effect of inhaling HPSCD on cell count T in puimonary parenchyma was studied by flow cytometry, Neither the total number of CDe + T cells (CD3 + CD4 +) nor the number of TMZ cells (CD2 + Key TISTZ + KOS +)
    were modified, suggesting the absence of significant T cell death following inhalations of HPECD (Figure 1F) These results demonstrate the effect of HFBCD on allergen-induced inflammation and hyperreactivity and were confirmed in another model. of allergen exposure using [nebulized ovalbumin {Figure ZA), In this model, inhalations of HPBCD also significantly reduced ovalbumin-induced airway hyperreactivity {Figure 28} and cell number inflammatory diseases in BALF as well as the number of Ecsinophils around the bronchi (figures 2C and 2D), Frotocois test of example 1 Mouse
    Male BALS / c mice 6 to 8 weeks old were purchased from Janvier laboratories (Saint-Berthevin, France). All mice were bred and housed in university facilities.
    All experiments and protocols have been previously approved by the local ethics committee (care and use of anima) of the University of Liege,
    - Antibody reagent
    Lyonhilized extracts of HDM (Dermatophagoides pteronyssinus) for animal studies were purchased from Greer laboratories (Lenoir, USA). Methachotin and lovalbumin come from Siema-Aldrich (Karlsruhe, Germany). HPECD {xeptose® HPB - molar substitution = 0.64) was kindly provided by Roguette {Lestrem, France}. Di +} - Glucose and Unéaire dextrin were purchased from
    VwWR (Louvain, Belgium}. Colorimetric Bral cell proliferation ELISA was supplied by Roche (Mannheim, Germany). TR-DPPE (Texas red 1,2-dipalmitoyl-sn-glycerc-3-phosphoethanotamine) and Le NED-PE (N- {7-ritrobenz-2-ox @ -1,3-ciazoi-dl} 1, $ - diheadecanoyl-sn-elycero-3-phosphoethanol-amine) were purchased from
    Invitrogen (Paisley, Scotland). DPH {1,6-diphenyl-1,3 5-hesatriene} and Laurdan (6-dodecanoyl-to-dimethyl-aminonaphthalene) were purchased from Molecular Probes {Invitrogen, Carlsbad, CA). POPC {1 -paimitoyl-Z-clsoyl-sn-glycero-3-phosphochotin}, sphingomysiine and cholesterol were ordered from Avanti Polar Lipids (Birmingham, UK) OVA-flucrescein isothiocyanate (FITC) was ordered from invitrogen (Paisley,
    Scotland). Anti-F4 / 80 (BMB) conjugated to shycoerythrin, anti-CD11c (N418) conjugated to APCoyanin and anti-MHCH (AF5-120.1) conjugated to PerCFP-Cy5.5 are from eBloscience (San Diego, USA). APCovanine-conjugated anti-CD3 {1742} and BV510-conjugated anti-CDe (RM4-5) were purchased from BD biosciences (Mississauga, Canada). Conical anti-iCO0S to [Alexa 647 (C398.dA) was obtained from Biolegend (San Diego, USAi, Anti-T {ST2 coniuguê to PE (DIS was ordered from MD Biosciences ( St Paul, USA) The type controls and antibodies were from the same manufacturer.
    2.462 Fc receptor antibodies were produced in-house, Flow cytomeetris
    Staining reactions were performed at 4 ° C. Cells were preincubated with Fe 2.462 receptor antibodies to reduce nonspecific binding.
    Data were analyzed using the Flowlo software, Airway Inflammation Protocols Mice were lightly anesthetized with ioflurane and instilled intravenously.
    nasal (in) HDM extract {100 ve; 50 µl} in a healthy solution without endotoxin on days 0, 7 and 14. Mice were subjected to inhalation (generated by a Litrasonic nebulizer (Devilbiss 20001 from HPECD 10 mM or satine solution without endotoxin for 40 minutes between days 12 and 16, On day 14, they received the inhalation Th before the last institlation of HDM, After measurement of bronchial reactivity using the FlexiVent system, The mice were sacrificed on day 17, The mice were sacrificed on the 17th day. mice subjected to ovalbumin allergen received an Lp injection of 10 meg grade 5 ovalbumin and were exposed to grade 3 ovalbumin by inhalation between day 21 and day 25. Mice were treated with 10 mM HPBCD administered by inhalation between day 19 and 25. Following measurement of bronchial reactivity using the FlaxiVent system, mice were sacrificed on day 26. Measurement of bronchial reactivity 19 Mice were anesthetized by intraperitoneal injection of a email ketamine angel (10 me / ml, Meral, Brussels, Belgium) and xylazine (1 mg / ml, VMD, Arendonk, Belgium). A tracheostomy was performed by inserting a 20 gauge polyethylene catheter into the trachea. Mice were ventilated with a FlexiVent® ISCIREQ small animal ventilator, Montreal, Canada} as previously described (18). Respiratory parameters following methachoiin challenge (3, &, and 12 gr / l {or 24 st / 1} were assessed using a 3-second broadband signal to measure the impedance of input from 1 to 20.5 Hz and to calculate the parameters of the constant phase model (Quick-prime 3) Newtonian resistance {Rn} was the main parameter measured during the def.
    | Bronchoalveolar lavage fluid (BALF) Mice were sacrificed and bronchoalveolar lavage was performed with 0.05 mM PBS-EDTA (Calblochem, Darmstadt, Germany). The cells were collected by gentle manual aspiration. After centrifugation of the bronchoaiveolar fluid (RALF) {1200 rpm; 10 minutes ; € ° C} the cell pellet was resuspended in 0.5 ml of 0.05 mM PES-EDTA. Differential cell counts were performed on cytocentrifuged {Cytospin} preparations after Diff-Quick staining (Dade, Belgium). Puimonary Histology and Tissue Processing The left lung was excised and frozen in liquid nitrogen. The right lung was perfused with 4% paraformaldehyde, embedded in paraffin and used for histology. Sections 5 µm thick were cut from parsffin and stained with hematoxylin-eosin to estimate the extent of inflammation (18) and with Aician's blue (mucinel stain, Measurement of THZ cells in the lungs. To obtain single cell suspensions, the lungs were perfused with 10 ml of HBS5 through the right ventricle, ELBOWED with a razor into small pieces and digested for 1 hour at 37 ° C in 1 mg / ml of collagenase À (Roche) and 0, 05 mg / ml of DNasel (Roche) in the H8SS The leukocytes were enriched thanks to the Percoli gradient (Easycoll, Millipore) The TH2 cells were defined as CD3 + CD cells TISTZ + 18 KOS: The flow cytometry was carried out on a FACScanto H {Becton Dickinson, Mountain View, CAL, Absorption of Afergens and Migration of DEPs To assess the absorption of allergens by pulmonary DCs (F4 / 80- CD11c + MHCH- +) and migration of CD to LDLN, mice were injected with 100 µg of OVA-FITC.
    24 hours later, the lungs and LDLN were analyzed by flow cytometry for the presence of CD loaded with antigens (CD FITC +}, To assess the impact of HPBCD on the absorption of allergens and micrations of CD , mice were treated by inhalation of HPRCD on D-2, D-1 and 1 hour before Firstillation Ln, of OVA-FITC, Flow cytometry was performed on a FACScanto II (Becton Dickinson, Mountain View, CA) , Example 11: Inhaled HPSCD Reduces Allergen-Induced Bronchoconsiriction in Human Asthmatics Seventeen mild to moderate asthmatics sensitized to MHD were included in a double-blind crossover study including allergenic challenges with MHD, Surprisingly , patients showed a smaller decrease in FEV1 after MDM challenge ((0-360 min) FEV1-time curve (AUC) when treated with HPBCD inhalation compared to periods of placebo treatment { figure SB}. Analysis (AUC) of the decrease in VENS during the early and late phases after HDM challenge shows a predominant effect of HPBCD disruption on preventing the decrease in FEV1 during the late 32 phase reaction (Figure SC). , The maximum decrease in FEV1 and the mean percentage decrease in FEV1 after HDM challenge were calculated and found to be significantly lower in patients treated with HPBCD (Figures 5D and SE) These experiments show a significant effect of inhalation of HBBCD on prevention of allergen-induced FEV1 decrease in late phase, No significant difference between [HPBCD and placebo was observed during early bronchoconstriction phase, No significant change was observed in hematology, biochemistry serum, urinalysis, vital signs, ECG tests and auimonary radiography between treatment groups Test protocol for example 2 Kinic test procedures The clinical test protocols have been approved by an independent ethics committee (CHU Liège - University of Liège) in accordance with GCP, the Declaration of Helsinki and European regulations (EudralT) All participants have given their informed consent in writing before any procedure specific to the study, For the phase 1 clinical trial, 8 healthy subjects (4 women and 4 men) aged 18 to 48 were recruited and enrolled in the study at the CHU of Liège (Belgium). The patients were randomized and first received the placebo (NaCl 0.9%) or the HPBCD at 2.5 mM and 8 days later, the reverse treatment. After one week, all the patients received the HPBCD at 15 mM. One month later, all patients received the HPBCD at 15 mM for 5 consecutive ovens.
    The sterile, pyrogen-free HPBCD powder was diluted with 0.9% NaCl before being inhaled {8 mi} with a uitrasonic nebulizer (Deviibiss 2000). General symptoms, asthma scores {ACO}, dyspnea, chest x-ray, clinical biology, ECG, vital signs, spirometry, NO, sputum {induced by 4.5% NaCl) were analyzed after the treatment periods, The second clinical trial (phase Za - proof of concept} was a double-blind, crossover, placebo-controlled study, 17 patients with mild to moderate asthma were included in the study at two different sites { Liège University Hospital and Erasme University Hospital) in Belgium. Characterization visits consisted of recording dyspnea symptoms, ECG, chest x-ray, clinical biology, spirometry and analysis of vital signs. The PD20 (provocative dose which causes a 20% drop in FEV1 from the value of physiological saline alone to inhaled fallergene was determined, In order to determine the individual bronchial response to the allergen, a provocation test was performed with an extract of Dermatophagoldes pteronyssimus {Stallergen: Antony, France) diluted in a healthy sotonic solution whose reactivity index was between 0.2 and 5, Vallergene's PD2D was calculated from a cumulative dose-response curve , as previously described, LCataido et al, Matrix Metalloproteinase-®, but not tissue inhibitor of matrix metalioproteinase-1, increases in sputum from allergic asthma patients after allersic challenge, Chest, 2002; 123 (5 ): 1553-4. All healthy subjects received a cumulative concentration of Dermatophagoides pteronyssinus with a reactivity index of 6. After a wash period of 14 ovens, the patients were randomly divided into two groups and received either 15 mM HPBCD or a placebo {NaCl 0.3%) by inhalation (ultrasonic nebulizer (Devilbiss 20001) twice daily, At the end of this treatment period puimonary function (FEV1} was analyzed after allergic provocation (MDM) under the supervision of experienced respiratory clinical physicologists.
    FEV1 was measured after an allercen inhalation test at 5, 15, 30, 60, 120, 180, 240, 300 and 360 minutes.
    After a washout period of 28 days, patients received the reverse treatment for an additional 14 days and FEV1 after allergen challenge was assessed.
    All clinical parameters were examined after each treatment period.
    The endpoint of this proof of concept study was the change in FEV1 over a period of 0 to 360 minutes after the aflergic challenge.
    The FEV1 in the early phase (0-60 min) and in the late phase (182-360 min} was expressed as: area under the VENS versus time curve (AUC, maximum percent fall and mean percent fall ( calculate by dividing the area under the curve of the percent fall in FEV1 by the length of the response period.) A patient who received a placebo had a negative maximal decrease in FEV1 and a negative mean percent fall in FEV1, These negative values were truncated to 0. Patients had access to Be-agonist (salbutamol 100 us) throughout the study as treatment “as needed. Preparation and visualization of GUYs GUVs were prepared by electroformation.
    Briefly, 1 ml of a chloroform solution of SM / Chol / POPC (1: 1: 13 was spread on a glass coated with indium tin oxide.
    Fluorescent probes (TR-DPPE and N8D-PE} were added to the chioroform solution at a concentration of 9.1% mol / mol. The solution was dried in a vacuum chamber for 2.5. An electroforming chamber. was constructed using another indium tin oxide coated glass slide, with the conductive side facing the inside of the electroforming chamber, which was filled with 0.1 M sucrose solution Polydimethylsiioane containing 5% fumed silica was used to separate the two glass slides.
    The GUYs were cultured in a sinusoidal alternating current of 10 Hz and 1 V for 2 h at 60 ° C, The GUVs were analyzed under the Axioskop 40 microscope (Carl Zeiss, léna, Germany) with a Zeiss EC Plan-Neofluar® objective 40- / 0.75 and the images were recorded with a
    19 Nikon D5-5 M digital camera (Nikon, Tokyo, Japan), TR-DPPE was excited at 561 nm and analyzed at 617 nm, NED-PE was excited at 460 nm and analyzed at 535 nm .
    The separation of the phases (Id / io} was evaluated after incubation with the HPBCD at 5 IM, Organization and rigidity of the membranes of T cells
    To analyze the impact of HPBCD on the mobility and polarity of phospholipids at the level of the glycerol backbone, Jurkat cells were incubated with Laurdan.
    Briefly, Ix106 cells were seeded in 3 ml of RPM] 10% FRS 1% pen / strep and treated at 37 ° C with HPBCD (5 mA, After 3 h the medium was replaced and the cells were incubated. with 1.4 mcM Laurdan for 1 h at 37 ° C, GFex was determined at 37 ° C as a measure of membrane organization and moisture, as described in Lorent et al, Induction of Highly Curved Structures. in Relation to Membrane Permeabilization and Budding by the Triterpenoid Saponins, à- et à & -Hederin, The Joumal of Biological Chemistry 20132880205 14000-17, Lipid dynamics / fluidity of the acyl chain after inoubation of HPECD has been similarly reduced Using the DPH probe, anisotropy was determined at 37 ° C as a measure of membrane stiffness.
    In Vitro T Cell Prolferation Assay HPBCD was used at a concentration of 5 mM.
    This concentration was not associated with cytotoxicity (as measured after 48 h of incubation by incorporation of Brad), Naive CD4 + T cells were isolated from the spleen of Balb / c mice and purified with a MACS & negative selection kit. , 1.5x105 cells were seeded in a 96-well plate and inoubée with 5 mM HPBCD (in RDM] 10% FES 1% pen / strep) or with mileu alone for 3 h, The cells were then recovered and plated in a CD3-coated well (3 mes / rmi for 24 or 48 h with HPBCD {5 mA} or with the culture medium alone at 37 25% CO2. During the last 2 hours of the proliferation test, the BrdU was added to the medium and the incorporation was quantified by ELISA following the manufacturer's instructions. Other wells were used to assess the secretion of iL-2 (ELISA) in the medium after 24 and 48 h of anti-stimulation. -CDS, In vitro T cell stimulation test 19 Lymph node cells which drain the lungs were isolated from mice which had previously been confronted with HDM. These cells were re-stimulated in a 96-well plate with 30 meg of HDM in RPM] Supernatants were evaluated after 48 hours for secretion d'il, 1L-5 and 1-13 by ELISA, Statistical analysis Phase 2 clinical trial - inclusion and exclusion Inclusion criteria Male to female with mild to moderate asthma e Age: 18,765 years e No current smokers ( maximum tobacco consumption: 10 / year) "Sensitization to dust mites (Dermatophagoides Pteronyssinus) controls by RAST by poisoning tests No regular treatment of asthma (exception: short-acting bronchodiiators)" No dexacerbation of the asthma or infection of the respiratory tract during the & weeks preceding inclusion in the study of the body mass index {CM} 18 - 28 kg / m "No concomitant disease or vital signs abnormalities" Informed consent to give "Subject available during the study 38 Exclusion criteria
    "Any medication taken during the last 28 days> Active smokers or people dependent on any other drug" Drug allergy + Consumption of alcohol {> 2 glasses / day) and coffee {> 4 cups / day}> History of cardiac, renal and hepatic problems likely to interfere with the study "Concurrent participation in another study + No informed consent Data are presented as mean + SEM, unless otherwise indicated.
    Differences between mean values were estimated using a two-stage Manr-Whitney test (animal and in vitro experiments), unless otherwise noted.
    All animal experiments were repeated at least twice; n> 6 in each experimental group.
    The Friedman ANOVA test (single dose) and the signed row Wilcoxon test (multiple doses} were used to analyze the results obtained in the phase 1 clinical trial. The single row Wilcoxon test (unpaired pairs) was used. to assess intra-individual differences in the proof of concept clinical trial.
    A P value less than 0.05 was found to be significant. GraphPad Prism and Statistica software were used to analyze the results.
    The results are presented in Table 1 below: 28
    > # gi S 3 E = = 9 02 Se BR ne ®> SNSNSSS RRARG ONE & = aso OSS Ges ë F x 5 D pa 2 10 N Si ZONDEN YT “= ENGS EZ WE a HO OH OH HR S 8 ® sÉs- = enhæo ELL BSÉÈSSE8 © s 2 5 Ss DEF 5 = UF & == 243 $ E 5 = £ 5 583 Ë S = SM NO OR NDR 4 2 fÉARRQGRS TAÉLRSRS 5 0 2 a HMNSSSSS ZAT GGS = 6 =; Li es: Bad NE ”HN OH OM OH BE + MH OH OH = en 2999 & 2 = SD rf TT BDT Tor es =%% & ges ZEN gp = = à Es <vi LE = qu # PF © =: 8 m = 2 = Ps De ON DE 00 me as N Sq © Zoas 5 Added ze Ë e = € a OT ROH = = ef = @ MN tl HO OH OH 5 a MHM MH A & ee ij id u = 2 2 9 872 ÉLRÈSS TER SEN ES PP SRS S 4% A DR EEE spurt 0 4 ox Ë Be En DS = € $ Ë uE = = = So & oi = ZS © S = €
    EE 33 SS 9 5 5 me ons zz fs © def del ee: Æ & es © ® ey © nn In SB in 4 Ë = = $ ”8 = x 8 = PO x + = vil een 2 vijl ce S & Ë« 5 5 EE = 8 2 = © € © SF ie © © © 5 2: 9 a ...… ÉSÉÉSEÉ 3 5 5 0 SL = 5 UE a ES ZESSEE 3 SES SEE Sas SEES 9 mis 8 2 6 CREATE = LEES SZ = - Rn nn £ a = ROM an EE * DOW 05 EE 2 u to EN to Oh 2 N to EL% kn 2 OL X SE © DD © SE 9 9 25 © © Sas ge SS SC = Bains SS N = & See min g BZT = A> if AEL 65 237908 2 297074 ss É sou “wee == © see Se, {DE BE CÉgégé 5 SSS = nm 5. = 3 EST E = ETS SE = En Ë A Ee Lu = = er = > == = wu Oe A 3 DE 5289 3555% ÿ SSRI LO A m 5 73 tai Let 5 5 5 yes Ss Pe xs SE 79 nd dpi SG ADD eu ST
    权利要求:
    Claims (1)
    [1]
    ; BE2021 / 5463
    COMPLAINTS
    1. Inhalable cyclodextrin or A pharmaceutically acceptable derivative thereof.
    ci, for use in the treatment or prevention of late phase bronchoconstriction in allergen-induced asthma.
    2 Cyclodextrin according to claim 1, in which the cyclodextrin is hydroxypronyl-beta-cyclodestrine.
    3. The cyclodextrin of one of the preceding claims, in which the cyclodextrin is an inhalable AGUELSS solution.
    4. Cyclodexirin according to claim 4, in which the cyclodextrin concentration is between 5 milimoles and 50 millimoles.
    5. Cyclodextrin according to claim 4, in which the concentration of cyclodextrin is between 7 millimoles and 40 millimoles, 6, Cyciodexirin according to claim 4, in which the concentration of +5 cyclocextrin is between 10 millimoles and 30 millimoles, #. The cyclodextrin of one of the preceding claims, wherein the tyclodextrin is a puiver dried powder.
    8. The cyclodextrin of one of the preceding claims in puimonary tissue, in the mouths the cyclodextrin is administered in an amount effective to reduce the order of the membrane in the cells.
    9. The cyclodextrin of one of the preceding claims, wherein the cyclodextrin is administered by inhalation in the amount of 0.1 to 20 me per day,
    10. The cyclodextrin of one of the preceding claims, wherein the cyclodextrin is administered by inhalation in the amount of 0.5 to 20 me per day.
    11. The cyclodextrin of one of the preceding claims, wherein the cyclodextrin is administered by inhalation in the amount of 1 me to 10 me per oven.
    12. The cyclodextrin of one of the preceding claims, in which the cyclodextrin is administered to children aged two years or less by inhalation in the amount of 9.1 me to 0.5 me per day,
    13. The cyclodextrin of one of the preceding claims, in laguells the cyclodextrin is administered to children aged two to six years by inhalation in the amount of 0.5 me to 1 me per day, 14, The cyclodextrin of one of the preceding claims, wherein the cyclodextrin is administered to children aged 6 to 14 years by inhalation in the amount of 1 mg to 2 me per oven.
    15. The cyvclodextrin of one of the preceding claims, wherein the cyclodextrin is administered from 0.1 mg to 15 me per day in mild to moderate asthma induced by an allergen and 1 mg to 30 me in asthma. severe allergen induced. 3
    类似技术:
    公开号 | 公开日 | 专利标题
    EP3082831B1|2021-01-06|Compositions comprising methyl-cyclodextrines to treat or prevent diseases by enhancement of the hdl-cholesterol level
    McAllen et al.1974|Steroid aerosols in asthma: an assessment of betamethasone valerate and a 12-month study of patients on maintenance treatment
    RU2299731C2|2007-05-27|Agonists of nicotine receptors in treatment of inflammatory diseases
    FR2962909A1|2012-01-27|PHARMACEUTICAL ASSOCIATION COMPOSITION AND ITS USE IN METHODS FOR TREATING DISEASES OR DISORDERS ASSOCIATED WITH RESPIRATORY DISEASE OR DISEASE
    EP1206257B1|2004-11-03|Use of amino acids for making medicines for treatinginsulin-resistance
    BE1028268B1|2021-12-02|Cyclodextrin used in the treatment and prevention of late stage bronchoconstriction in allergenic asthma
    EP3313414A1|2018-05-02|Kit for treating sepsis and/or any systemic | or damaging cellular hyperinflammation
    EP2906230B1|2017-06-07|Use of an argon/xenon mixture to prevent or treat the neurological consequences of a septic shock
    EP3713555A1|2020-09-30|Quercetin-based composition for treating rhinosinusitis
    WO2017178630A1|2017-10-19|Use of fenofibric acid in the treatment of hepatic diseases
    US9789158B2|2017-10-17|Applications of recombined Ganoderma lucidum immunoregulation protein in preparing drugs for treating tissue fibrosis
    WO2017158179A1|2017-09-21|Use of an h4 agonist molecule for the treatment of idiopathic pulmonary fibrosis
    FR3049866B1|2019-09-06|EXTRACT OF TOBACCO LEAVES AND USE FOR TREATMENT OF TOBACCO ADDICTION
    WO2000033810A1|2000-06-15|Use of vitamin b12 in a nasal composition for delivering active agents to the central nervous system
    EP3408373B1|2020-01-01|Bacterial strain as agents for preventing and/or treating respiratory disorders
    US20200383909A1|2020-12-10|Compositions and methods for treating eosinophilic disorders
    Seniutkin2017|Effects of Pirfenidone in a Mouse Liver Fibrosis Model
    CH702779A2|2012-02-29|Use of pentosan polysulfate sodium for the preparation of the medicament for the treatment of diabetic nephropathy
    Gharazi et al.2021|Protective effect of a formulation containing Pistacia atlantica oleo-gum-resin and honey on experimental model of acetic acid-induced colitis in rats
    Zhao et al.2022|Berberine ameliorates aGVHD by gut microbiota remodelling, TLR4 signalling suppression and colonic barrier repairment for NLRP3 inflammasome inhibition
    Underner et al.2011|Tabac non fumé
    CA3123477A1|2020-06-25|Saccharomyces cerevisiae yeast strain for the treatment and/or prevention of oropharyngeal candidiasis
    WO2021001518A1|2021-01-07|Pxr ligands for the prevention or treatment of metabolic disorders
    WO2022049581A1|2022-03-10|Composition comprising cannabinoids, and/or terpens, and methods of using same
    FR3022457A1|2015-12-25|USE OF CANNABIS FOR THE TREATMENT OF ACHALASIA
    同族专利:
    公开号 | 公开日
    US20210386668A1|2021-12-16|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    2022-01-19| FG| Patent granted|Effective date: 20211202 |
    优先权:
    申请号 | 申请日 | 专利标题
    BE202005430|2020-06-15|
    [返回顶部]